Gene Therapy Offers Lifelong Cholesterol Reduction
An experimental gene therapy called VERVE-102, using base editing of the PCSK9 gene, shows promise in reducing LDL cholesterol in clinical trials, especially for those with familial hypercholesterolemia and premature coronary artery disease, with ongoing studies and potential for broad application.
